The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10520 malaria professionals are enjoying the free benefits of MalariaWorld today


Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-γ/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection

July 21, 2010 - 07:09 -- Patrick Sampao
James F., Michele D., et al.
Vaccine, Volume 28, Issue 31, 12 July 2010, Pages 5135-5144

Although the optimal antigen dose of LSA-NRC may not have been selected for the challenge portion of the protocol, further vaccine development based upon LSA-1 should not be excluded and should include alternative vaccine platforms able to elicit additional effector mechanisms such as CD8+ T cells.

Medical Treatment: 
Subscribe to RSS - antigen-1